Nutriband increases existing credit line to $5M

Nutriband expanded its existing Credit Line facility to $5M to fund the continued development and regulatory submission process for the Company’s patented lead product platform, AVERSA Fentanyl, an abuse-deterrent fentanyl transdermal system. The Company is targeting FDA submission for AVERSA Fentanyl in the first half of 2024. AVERSA Fentanyl is the flagship product of the Company’s AVERSA Platform.